MedPath

A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer

Not Applicable
Completed
Conditions
Localized Stage I-III Esophageal Cancer
Gastroesophageal Junction Cancer
Registration Number
NCT02027948
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Brief Summary

Patients with esophageal and gastroesophageal junction (GEJ) cancer often have weight loss, swallowing problems, and poor appetite. This may affect their ability to tolerate cancer treatment.

The purpose of this study is to see if the researchers can apply a set of nutrition guidelines designed specifically for patients with cancer who are older than 65 years of age. The questions will allow them to assess the nutritional status and make appropriate referrals. If the patients are having swallowing problems or losing weight, the researchers want to address the nutritional problems early in the course of their treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Patients must be ≥ age of 65; no maximum age limit.
  • Patients who will receive induction chemotherapy followed by combined chemoradiotherapy at MSKCC for localized stage I-III esophageal or gastroesophageal junction cancer.
  • Patients can receive chemoradiotherapy preoperatively prior to surgical resection or as definitive/primary chemoradiotherapy.
  • Patients can be KPS ≥60, as long as primary provider feels that patient is candidate for combined modality chemoradiotherapy
  • Be able to provide informed consent
Exclusion Criteria
  • Enrolled on a phase I trial
  • Patients with a feeding tube previously placed.
  • Not English-speaking

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
feasibility of a nutritional management algorithm2 years

Various validated assessments of nutritional status have been described. Nutritional status can be evaluated using: 1) anthropometric measures (i.e. weight loss, body mass index (BMI), triceps skin fold thickness, arm circumference), 2) immunological measurements (i.e. absolute lymphocyte count), and 3) serum protein markers (i.e. albumin, prealbumin, transferrin, and retinol-binding protein)

Secondary Outcome Measures
NameTimeMethod
treatment toxicity of chemoradiotherapy2 years

Treatment toxicity of chemoradiotherapy will be summarized using descriptive statistics. Binomial proportions along with exact 95% confidence intervals will be estimated for proportions. Toxicity during the induction chemotherapy phase will be correlated with the baseline nutritional status (as determined by the MNA assessment) and baseline functional status using Fisher's exact test for categorical measures and Wilcoxon's rank sum test for numeric measures. Similarly, toxicity during chemoradiotherapy will be correlated with baseline MNA and functional status as well as with the malnutrition assessment using Fisher's exact test for categorical measures and Wilcoxon rank sum test for numeric measures.

Trial Locations

Locations (7)

Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only)

🇺🇸

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Consent Only)

🇺🇸

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Consent only)

🇺🇸

Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only)

🇺🇸

Commack, New York, United States

Memorial Sloan Kettering Cancer Center at Commack (Consent Only)

🇺🇸

Commack, New York, United States

Memorial Sloan Kettering West Harrison (Consent Only)

🇺🇸

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only)
🇺🇸Basking Ridge, New Jersey, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.